Expanded Access for CC-4047
- Conditions
- Multiple Myeloma
- Registration Number
- NCT03723096
- Lead Sponsor
- Celgene
- Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-4047.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of CC-4047 in multiple myeloma treatment?
How does CC-4047 compare to standard-of-care therapies like bortezomib in multiple myeloma outcomes?
Which biomarkers are associated with CC-4047 response in multiple myeloma patients?
What are the most common adverse events reported with CC-4047 in expanded access programs?
Are there combination therapies involving CC-4047 and other Celgene compounds for multiple myeloma?
Trial Locations
- Locations (1)
Celgene
🇺🇸Summit, New Jersey, United States
Celgene🇺🇸Summit, New Jersey, United States